PHRI at EASD 2019

PHRI research on diabetes is well represented at the 55th annual meeting of the European Association for the Study of Diabetes (EASD 2019) in Barcelona, Spain Sept. 16 – 20, 2019.

Natalia McInnes and Hertzel Gerstein

  • Unique features and findings of the long-term REWIND (researching cardiovascular events with a weekly incretin in diabetes) trial, presented by Hertzel Gerstein. Sept. 19, 12:00 Barcelona time, Vilanova Hall.
  • REMIT-DAPA trial (diabetes regression and remission following a short-term intensive metabolic intervention with insulin glargine, metformin and dapagliflozin) poster presentation by Natalia McInnes. Sept. 19, 13:15.
  • Angiotensin-converting enzyme and type 2 diabetes risk: a Mendelian randomization study: oral presentation by Marie Pigeyre, Sept. 19, 15:00, Serrano-Rios Hall.
  • Novel biomarkers predicting renal decline in people with dysglycemia in the ORIGIN trial: oral presentation by Hertzel Gerstein, Sept. 19, 15:30, Vilanova Hall.

Next month, PHRI will share research at the 2019 Diabetes Canada/Canadian Society of Endocrinology and Metabolism professional conference, in Winnipeg, Canada.